Latest news
Biosimilars drive Biocon’s Q1 revenue growth, net profit up at ₹141 cr - BusinessLineBusinessLine · Sat, 08 Aug 2026 11:30:28 GMTEarnings Miss: Biocon Limited Missed EPS By 24% And Analysts Are Revising Their Forecasts - simplywall.stsimplywall.st · Sat, 08 Aug 2026 03:47:22 GMTBiocon announces commercial launch of Yesafili in USA - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 18:16:32 GMTBiocon Bullish On US Eylea Biosimilar, Says Regulatory Shift Sharpens Edge For Incumbents - insights.citeline.cominsights.citeline.com · Fri, 07 Aug 2026 09:18:17 GMTBiocon Expects Stronger H2 Growth on US Biosimilar Launches - Chemical Industry DigestChemical Industry Digest · Fri, 07 Aug 2026 07:22:15 GMTBiocon reports over 4-fold rise in profit on biopharma growth - Deccan HeraldDeccan Herald · Fri, 07 Aug 2026 00:37:52 GMTBiocon Reports Q1 Net Profit of ₹141 Crore as Revenue Reaches ₹4,336 Crore - SahiSahi · Thu, 06 Aug 2026 18:15:58 GMTBiocon sees stronger H2 on US biosimilar launches, regulatory easing - BusinessLineBusinessLine · Thu, 06 Aug 2026 13:54:35 GMT